Tag Archive for: financing

Research_team-NK-IO Ltd. © NK-IO Ltd

British NK cell therapy specialist NK:IO Ltd has added a £1.2m seed investment led by Cancer Research Horizons, bringing total seed funding to £5.1m.

Emmanuel Ladent, CEO of Carbios. © Carbios SAS

In an oversubscribed capital increase, Carbios SAS has raised €141m, the largest on Euronext growth since 2015.

Herpes simplex vector. © EG 427

Paris-based gene therapy vector specialist EG 427 SAS has closed a Series A financing at €18m raising additional €5m in the final closing.

Mechanism of action (MOA) of sCD83. © Alexander Steinkasserer/Univ. Erlangen

Mallia Therapeutics GmbH has raised seed money to accelerate preclinical research and start Phase I testing of a baldness cure with unique MOA named soluble CD83.

Scanning electron micrograph of F. prausnitzii © MIMA 2 experimental facility, INSERM, T. Meylheuc

Exeliom Biosciences, a French company focused on the microbiome-immunomodulation axis to develop next-generation immunotherapies, has announced the closing of its €24m (US$26m) Series A financing to advance the clinical development of its therapeutic pipeline, including several clinical trials of EXL01, a novel bacterial immunotherapy with applications in cancer and infectious diseases.

©Pixabay.com

Dutch venture builder NLC has announced a €20m first close for its new Health Impact Fund, from which it will invest in 40 startups, both new investments and follow-on. It’s targeting a final close of €100m later this year.

©Carthera

Carthera, a Sorbonne spin-off and developer of an innovative ultrasound-based medical device for the treatment of a wide range of brain disorders, today announced the successful completion of its €37.5m ($40m) Series B financing round.

From left: Alexis Ducarouge, CTO;  Christian Allouche, CEO; Nor-Eddine Regnard, CMO. © Gleamer SAS

French AI-powered radiography diagnostics specialist Gleamer SAS has raises €27m in Series B round to expand its portfolio and accelerate its expansion.

Astraveus CEO Jérémie Laurant. © Astraveus

French cell and gene therapy manufacturing specialist Astraveus SAS had raises €16.5m in seed money to advance its automated, microfluidic Cell and Gene Therapy manufacturing platform.

@ nattanan23/pixabay.com

Carbios SAS has announced a capital increase of around €122m that may grow up  to €141m.